{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T20:29:22Z","timestamp":1790022562124,"version":"4.0.1"},"reference-count":38,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2021,10,27]],"date-time":"2021-10-27T00:00:00Z","timestamp":1635292800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Journal of Viral Hepatitis"],"published-print":{"date-parts":[[2022,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Direct\u2010acting antivirals (DAAs) have recently been developed to treat hepatitis C virus (HCV) infection, and interferon\u2010free DAA treatment has improved liver function of HCV patients. The risk of hepatocellular carcinoma (HCC) occurrence following HCV eradication has been previously reported, but HCC may have been missed following imaging diagnosis before DAA administration in previous studies. Therefore, the present study aimed to identify definite predictors of HCC occurrence \u22651\u00a0year after DAA treatment. Among 956 patients receiving DAAs for HCV infection, 567 patients who achieved sustained virologic response with no history of HCC treatment were enrolled in this study between September 2014 and July 2021. The incidence of HCC in HCV\u2010infected patients \u22651\u00a0year following DAA treatment, and the predictors contributing to HCC occurrence were identified using clinical characteristics and blood test results. In the present study, 25 patients developed HCC. The incidence of HCC was 1.4%, 3.2%, 4.9% and 6.8% at 2, 3, 4 and 5\u00a0years, respectively, from the end of treatment with DAAs. Multivariate logistic analysis revealed serum \u03b1\u2010fetoprotein level at end of treatment (EOT\u2010AFP) &gt;3.8\u00a0ng\/ml \u22651\u00a0year following treatment with DAAs (HR, 9.7; <jats:italic>p<\/jats:italic>\u00a0&lt;\u00a0.0001) as an independent factor that may contribute to HCC occurrence following DAA treatment. In conclusion, serum EOT\u2010AFP level may serve an important role in determining the risk of HCC occurrence \u22651\u00a0year after DAA treatment. Regular examinations are required even if serum EOT\u2010AFP level is low at treatment completion.<\/jats:p>","DOI":"10.1111\/jvh.13625","type":"journal-article","created":{"date-parts":[[2021,10,20]],"date-time":"2021-10-20T18:46:33Z","timestamp":1634755593000},"page":"35-42","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Serum \u03b1\u2010fetoprotein level at treatment completion is a useful predictor of hepatocellular carcinoma occurrence more than one year after hepatitis C virus eradication by direct\u2010acting antiviral treatment"],"prefix":"10.1111","volume":"29","author":[{"given":"Akifumi","family":"Kuwano","sequence":"first","affiliation":[{"name":"Department of Hepatology Aso Iizuka Hospital Iizuka Fukuoka Japan"},{"name":"Department of Medicine and Bioregulatory Science Graduate School of Medical Sciences Kyushu University Higashi\u2010ku Fukuoka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayoshi","family":"Yada","sequence":"additional","affiliation":[{"name":"Department of Hepatology Aso Iizuka Hospital Iizuka Fukuoka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigehiro","family":"Nagasawa","sequence":"additional","affiliation":[{"name":"Department of Hepatology Aso Iizuka Hospital Iizuka Fukuoka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kosuke","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Department of Hepatology Aso Iizuka Hospital Iizuka Fukuoka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Morita","sequence":"additional","affiliation":[{"name":"Department of Hepatology Aso Iizuka Hospital Iizuka Fukuoka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihide","family":"Masumoto","sequence":"additional","affiliation":[{"name":"Department of Hepatology Aso Iizuka Hospital Iizuka Fukuoka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenta","family":"Motomura","sequence":"additional","affiliation":[{"name":"Department of Hepatology Aso Iizuka Hospital Iizuka Fukuoka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,10,27]]},"reference":[{"key":"e_1_2_11_2_1","first-page":"425","article-title":"Hepatitis C\u2010global prevalence (update)","volume":"74","author":"World Health Organization","year":"1999","journal-title":"Wkly Epidemiol Rec"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2003.12.049"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/155.4.323"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1713263"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa020047"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-140-5-200403020-00010"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(01)06102-5"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp1400986"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2016.06.015"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.01.028"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.14593"},{"issue":"17","key":"e_1_2_11_13_1","first-page":"32273","article-title":"HCV eradication induced by direct\u2010acting antiviral agents reduces the risk of hepatocellular carcinoma","volume":"0168","author":"Ioannou GN","year":"2017","journal-title":"J Hepatol"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2017.06.012"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2018.04.008"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2016.06.009"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.11.011"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2016.04.008"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v24.i24.2582"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.30823"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2019.02.046"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2018.10.014"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32111-1"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27366"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21669"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28535"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.26442"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2013.11.033"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0243473"},{"issue":"3","key":"e_1_2_11_30_1","first-page":"2205","article-title":"Simple scoring system for prediction of hepatocellular carcinoma occurrence after hepatitis C virus eradication by direct\u2010acting antiviral treatment: all Kagawa Liver Disease Group Study","volume":"19","author":"Tani J","year":"2020","journal-title":"Oncol Lett"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.3164\/jcbn.19-98"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-019-09939-2"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/hepr.13310"},{"key":"e_1_2_11_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/hepr.12839"},{"key":"e_1_2_11_35_1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000008696"},{"key":"e_1_2_11_36_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-020-10105-2"},{"key":"e_1_2_11_37_1","doi-asserted-by":"publisher","DOI":"10.15403\/jgld.2014.1121.281.hpc"},{"key":"e_1_2_11_38_1","doi-asserted-by":"publisher","DOI":"10.1111\/hepr.13278"},{"key":"e_1_2_11_39_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.14380"}],"container-title":["Journal of Viral Hepatitis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jvh.13625","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jvh.13625","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jvh.13625","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,25]],"date-time":"2023-08-25T10:50:22Z","timestamp":1692960622000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jvh.13625"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,27]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["10.1111\/jvh.13625"],"URL":"https:\/\/doi.org\/10.1111\/jvh.13625","archive":["Portico"],"relation":{},"ISSN":["1352-0504","1365-2893"],"issn-type":[{"value":"1352-0504","type":"print"},{"value":"1365-2893","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,27]]},"assertion":[{"value":"2021-08-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-09-21","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-10-27","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}